Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 15, 2022
Reporting Period: Event date of September 15, 2022
This filing reports the adoption of the Third Amended and Restated By-laws by the Board of Directors, effective immediately.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance amendments and does not contain financial performance data.
Material Changes
The primary material change is the amendment to the Company's By-laws, effective September 15, 2022. Key provisions include:
- Remote Meetings: Permits the annual stockholder meeting to be held solely by means of remote communication.
- Voting Thresholds: Updates the required vote for all matters to a majority of votes cast by holders present in person or by proxy, rather than a majority of the number of shares present.
- Abstentions and Non-Votes: Specifies that abstentions and broker non-votes shall be excluded regarding the subject matter.
- Stockholder Proposals: Sets forth new procedures and conditions for stockholder proposals and director nominations.
- Notice Procedures: Permits notice to be given by electronic transmission.
- Exclusive Forum: Designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for specified claims against the Company, its directors, officers, employees, and stockholders.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors beyond the legal implications of the new exclusive forum provision. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the full text of the Third Amended and Restated By-laws filed as Exhibit 3.1.
- Review the marked copy of the By-laws (Exhibit 3.2) to understand specific textual changes.
- Confirm the impact of the Delaware Court of Chancery exclusive forum provision on shareholder litigation rights.
- Check subsequent filings for the implementation of remote voting procedures for the next annual meeting.